Skip to main content

Table 4 Total cumulative dosing and treatment duration

From: Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

Safety population AC-1202
n = 86
  Placebo
n = 66
 
Total Cumulative Dose     
   Mean dose (grams) ± SD 3555.00 ± 1883.89   4424.55 ± 1326.78  
   Median 4515   4965  
   Median percent of intended dose 86.99%   95.66%  
   (Range) (30, 5460)   (150, 5550)  
Treatment Duration (days)     
   N* 82   66  
   Mean ± SD 71.66 ± 31.08   83.91 ± 18.26  
   Median 90.0   91.0  
   (Range) (1, 101)   (5, 103)  
Genotyped population APOE4(-)
n = 36
APOE4(+)
n = 39
APOE4(-)
n = 27
APOE4(+)
n = 33
Total Cumulative Dose     
   Mean dose (grams) 3049.17 4015.38 4382.22 4375.45
   ± SD ± 2076.41 ± 1531.93 1398.93 ± 1386.91
   Median 3780 4740 4950 4980
   Median percent of intended dose 72.8% 91.3% 95.4% 95.6%
   Range (grams) 30 – 5430 30 – 5460 240 – 5490 150 – 5550
Treatment Duration (days)     
   N* 34 38 27 33
   Mean 64.1 77.8 87.1 80.3
   ± SD ± 36.44 ± 24.3 ± 11.2 +23.3
   Median 88.0 90.0 91.0 91.0
   Range (days) 3 – 96 1 – 101 56 – 103 5 – 100
  1. *Treatment duration was unknown for 4 AC-1202 subjects for whom last date of study medication was not recorded